Search for a trial

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients with Inadequate Response to Prior Preventive Treatments

The primary objective of the study is to demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult patients with migraine with inadequate response to 2 to 4 classes of prior preventive…

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled,
Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens
(Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the
Prevention of Episodic Cluster Headache

The primary objective of this study is to demonstrate the efficacy of fremanezumab in the prevention of ECH in adult patients. The primary efficacy endpoint of this study is the mean change from baseline (run-in period) in the weekly average number…

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled,
Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens
(Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the
Prevention of Chronic Cluster Headache

The primary objective of this study is to demonstrate the efficacy of fremanezumab in the prevention of CCH in adult patients:- The primary efficacy endpoint of this study is the mean change from baseline (run-in period) in the monthly average…

A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety and Efficacy of
TEV-48125 for the Prevention of Cluster Headache

As of 15 June 2018, only patients from the ECH study (Study TV48125 CNS 30056) will enroll in this study for active treatment. As of 15 June 2018, all CCH patients included in this study have been asked to discontinue treatment, and are encouraged…